Jill E Long1, Min S Lee1, Diana L Blithe1. 1. Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: The advent of new methods of male contraception would increase contraceptive options for men and women and advance male contraceptive agency. Pharmaceutical R&D for male contraception has been dormant since the 1990s. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969 and supports most ongoing hormonal male contraceptive development. Nonhormonal methods are in earlier stages of development. CONTENT: Several hormonal male contraceptive agents have entered clinical trials. Novel single agent products being evaluated include dimethandrolone undecanoate, 11β-methyl-nortestosterone dodecylcarbonate, and 7α-methyl-19-nortestosterone. A contraceptive efficacy trial of Nestorone®/testosterone gel is underway. Potential nonhormonal methods are at preclinical stages of development. Many nonhormonal male contraceptive targets that affect sperm production, sperm function, or sperm transport have been identified. SUMMARY: NICHD supports development of reversible male contraceptive agents. Other organizations such as the World Health Organization, the Population Council, and the Male Contraception Initiative are pursuing male contraceptive development, but industry involvement remains limited. Published by Oxford University Press on behalf of the Endocrine Society 2021.
BACKGROUND: The advent of new methods of male contraception would increase contraceptive options for men and women and advance male contraceptive agency. Pharmaceutical R&D for male contraception has been dormant since the 1990s. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969 and supports most ongoing hormonal male contraceptive development. Nonhormonal methods are in earlier stages of development. CONTENT: Several hormonal male contraceptive agents have entered clinical trials. Novel single agent products being evaluated include dimethandrolone undecanoate, 11β-methyl-nortestosterone dodecylcarbonate, and 7α-methyl-19-nortestosterone. A contraceptive efficacy trial of Nestorone®/testosterone gel is underway. Potential nonhormonal methods are at preclinical stages of development. Many nonhormonal male contraceptive targets that affect sperm production, sperm function, or sperm transport have been identified. SUMMARY: NICHD supports development of reversible male contraceptive agents. Other organizations such as the World Health Organization, the Population Council, and the Male Contraception Initiative are pursuing male contraceptive development, but industry involvement remains limited. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Entities:
Keywords:
contraception; male contraception; nonhormonal contraceptive development; sperm
Authors: Hermann M Behre; Michael Zitzmann; Richard A Anderson; David J Handelsman; Silvia W Lestari; Robert I McLachlan; M Cristina Meriggiola; Man Mohan Misro; Gabriela Noe; Frederick C W Wu; Mario Philip R Festin; Ndema A Habib; Kirsten M Vogelsong; Marianne M Callahan; Kim A Linton; Doug S Colvard Journal: J Clin Endocrinol Metab Date: 2016-10-27 Impact factor: 5.958
Authors: J Aaron Crapster; Paul G Rack; Zane J Hellmann; Austen D Le; Christopher M Adams; Ryan D Leib; Joshua E Elias; John Perrino; Barry Behr; Yanfeng Li; Jennifer Lin; Hong Zeng; James K Chen Journal: Elife Date: 2020-03-12 Impact factor: 8.140
Authors: Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Brian T Nguyen; Maritza T Farrant; Bradley D Anawalt; Fiona Yuen; Arthi Thirumalai; John K Amory; Ronald S Swerdloff; William J Bremner; Peter Y Liu; Diana L Blithe; Stephanie T Page; Christina Wang Journal: Contraception Date: 2020-04-13 Impact factor: 3.375
Authors: Raymond K Hau; Joseph S Tash; Gunda I Georg; Stephen H Wright; Nathan J Cherrington Journal: J Pharmacol Exp Ther Date: 2022-07-02 Impact factor: 4.402
Authors: A M Isidori; A Aversa; A Calogero; A Ferlin; S Francavilla; F Lanfranco; R Pivonello; V Rochira; G Corona; M Maggi Journal: J Endocrinol Invest Date: 2022-08-26 Impact factor: 5.467
Authors: Giovanni Corona; Giulia Rastrelli; Sara Marchiani; Sandra Filippi; Annamaria Morelli; Erica Sarchielli; Alessandra Sforza; Linda Vignozzi; Mario Maggi Journal: World J Mens Health Date: 2021-06-01 Impact factor: 5.400